Avacta Group receives ‘excellent’ initial data from ongoing COVID-19 clinical studies
(AVCT ) said it has seen “extremely encouraging” results from first data received for its SARS-CoV-2 rapid antigen test from its ongoing clinical studies in Europe and the UK.
The Affimer® biotherapeutics developer said the data showed an ‘excellent performance of the test in identifying patients with an infectious viral load and no false positive results.’
The Company’s SARS-CoV-2 rapid antigen test has been developed to identify infectious individuals so that they can isolate promptly and reduce the spread of COVID-19.
A recent report from the Liverpool Covid SMART Pilot Study1 indicates that individuals with COVID-19 infection had a significant chance of infecting their contacts if they had a viral load measured by PCR, called the Ct value (cycle threshold value), of approximately 25 or lower.
The Ct value indicates how many polymerase chain reaction (PCR) cycles are required to amplify the viral ribonucleic acid (RNA), which is what the genetic material for SARS-CoV-2 is encoded in, so that it can be detected and a lower Ct value indicates a higher viral load.
The initial evaluation of Avacta’s lateral flow rapid antigen test with clinical samples was conducted at an EU site and a UK site, respectively, using patient samples with viral loads confirmed by PCR.
Overall, 30 positive samples were tested with Ct values of 26 and below, with half of those in the range 22-26, and the lateral flow test identified 29/30 of these correctly as positive. Avacta said this indicates a clinical sensitivity of 96.7% for samples with a Ct value below 26.
Shares in Avacta Group have increased by nearly 30% in value since the beginning of February 2021 and were trading 19.74% higher this morning at 185p following the news.
‘Importantly,’ the Group noted, ‘out of a total of 26 negative samples tested with the lateral flow device, the test correctly identified all 26 as negative, giving a clinical specificity of 100%.’
‘High specificity is critical for a lateral flow test for mass screening so that large numbers of false positives are not generated which would create a major burden on follow-on testing resources, and result in a significant socio-economic cost of unnecessarily isolating people.’
As a result of ‘excellent initial data’, the Company said it will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year.
"I am delighted with the performance of the test with clinical samples which is extremely encouraging,” commented Dr Alastair Smith, Chief Executive Officer of Avacta Group.
He added, “On the basis of these initial clinical studies, the lateral flow test shows very good sensitivity in the infectious range of viral loads including at the lower infectious loads with Ct values of 23-26 which compares very favourably with the data reported in the Liverpool Covid SMART Pilot Study report.
These data from the first clinical studies will allow us to quickly progress with confidence into the full clinical validation of the test, manufactured at scale, at our clinical trial sites in the UK and the EU. I am confident that these data will accelerate our commercial discussions regarding the roll-out of the test when it is approved for professional use.”
Follow News & Updates from here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.